IL6 Human ELISA Kit

Name: IL6 Human ELISA Kit
SKU: DEIA1536
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Cell lysate and tissue lysate

Species Reactivity

Human

Detection Method

Sandwich-ELISA

Intended Use

The IL6 human kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human IL-6 cell lysate and tissue lysate.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Human IL-6 Microplate	1 Plate	4°C/-20°C
2	Human IL-6 Standard Protein	2 vials	4°C/-20°C
3	Human IL-6 Detection Antibody	2 vials	4°C/-20°C
4	Wash Buffer (20X)	25 mL	4°C/-20°C
5	HRP-Streptavidin	200 μL	4°C/-20°C
6	TMB One-Step Substrate Reagent	12 mL	4°C/-20°C
7	Stop Solution	8 mL	4°C/-20°C
8	Sample Diluent Buffer (5X)	10 mL	4°C/-20°C
9	Assay Diluent B (5X)	15 mL	4°C/-20°C
10	Lysis Buffer (2X)	5 mL	4°C/-20°C
11	96-Well Plate Sealing Film	2 films

Storage

The entire kit may be stored at -20°C for up to 1 year from the date of shipment. Avoid repeated freeze-thaw cycles. The kit may be stored at 4°C for up to 6 months. For extended storage, it is recommended to store at -80°C. For prepared reagent storage, see Reagents And Materials Provided.

Sensitivity

The minimum detectable dose of Human IL-6 was determined to be 3 pg/ml.
Minimum detectable dose is defined as the analyte concentration resulting in an absorbance that is 2 standard deviations higher than that of the blank (diluent buffer).

Standard Curve

Citations

Have you cited DEIA1536 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Associations of IL6 rs1800795, BLK rs13277113, TIMP3 rs9621532, IL1RL1 rs1041973 and IL1RAP rs4624606 single gene polymorphisms with laryngeal squamous cell carcinoma

GENE

Authors: Pasvenskaite, Agne; Vilkeviciute, Alvita; Liutkeviciene, Rasa; Gedvilaite, Greta; Liutkevicius, Vykintas; Uloza, Virgilijus

Abstract

Objective: Survival rate of laryngeal squamous cell carcinoma (LSCC) patients is not improving. To understand more complete biology of LSCC, studies focused on identification of new specific and prognostic markers are performed. The aim of current study was to evaluate the impact of five different single nucleotide polymorphisms (SNP) (IL6 rs1800795, BLK rs13277113, TIMP3 rs9621532, IL1RL1 rs1041973 and IL1RAP rs4624606) on LSCC development. Material and methods: A total of 891 subjects (353 histologically verified LSCC patients and 538 healthy controls) were involved in this study. The genotyping was carried out using the real-time-PCR. Results: Statistical analysis revealed statistically significant associations between TIMP3 rs96215332 variants and LSCC in the codominant (OR = 0.600; 95% CI: 0.390-0.922; p = 0.020), overdominant (OR = 0.599; 95% CI: 0.390-0.922; p = 0.020) and additive (OR = 0.675; 95% CI: 0.459-0.991; p = 0.045) models. Also, significant variants of IL1RAP rs4624606 were determined in the codominant (OR = 1.372; 95% CI: 1.031-1.827; p = 0.030), overdominant (OR = 1.353; 95% CI: 1.018-1.798; p = 0.037) and additive (OR = 1.337; 95% CI: 1.038-1.724; p = 0.025) models. Conclusion: Results of the current study indicate significant associations between TIMP3 rs9621532 and IL1RAP rs4624606 gene polymorphisms and LSCC development.

Human Isogenic Cell Line Models for Neutrophils and Myeloid-Derived Suppressor Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Authors: Zhang, Yuting; Wilt, Emily; Lu, Xin

Abstract

Neutrophils with immunosuppressive activity are polymorphonuclear myeloid-derived suppressor cells (MDSCs) and may contribute to the resistance to cancer immunotherapy. A major gap for understanding and targeting these cells is the paucity of cell line models with cardinal features of human immunosuppressive neutrophils and their normal counterparts, especially in an isogenic manner. To address this issue, we employ the human promyelocytic cell line HL60 and use DMSO and cytokines (granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin 6 (IL6)) to induce the formation of either neutrophils or MDSCs. The induced MDSCs are CD11b(+) CD33(+) HLA-DR-/low and are heterogeneous for CD15 and CD14 expression. The induced MDSCs abrogate IL2 production and activation-induced cell death of the human T cell line Jurkat stimulated by CD3/CD28 antibodies, whereas the induced neutrophils enhance IL2 production from Jurkat cells. The induced MDSCs upregulate the expression of C/EBP beta, STAT3, VEGFR1, FATP2 and S100A8. Lastly, the immunosuppressive activity of the induced MDSCs is inhibited by all-trans retinoic acid and STAT3 inhibitor BP-1-102 through cellular differentiation and dedifferentiation mechanisms, respectively. Together, our study establishes a human isogenic cell line system for neutrophils and MDSCs and this system is expected to facilitate future studies on the biology and therapeutics of human immunosuppressive neutrophils.